Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Myriad Genetics, Inc. (MYGN)

18.85   -0.79 (-4.02%) 11-28 16:00
Open: 19.32 Pre. Close: 19.64
High: 19.71 Low: 18.76
Volume: 376,936 Market Cap: 1,527(M)

Technical analysis

as of: 2022-11-28 4:41:43 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 25.89     One year: 30.24
Support: Support1: 17.97    Support2: 15.38
Resistance: Resistance1: 22.17    Resistance2: 25.89
Pivot: 19.38
Moving Average: MA(5): 19.4     MA(20): 18.88
MA(100): 21.62     MA(250): 22.68
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 55.7     %D(3): 59.5
RSI: RSI(14): 47
52-week: High: 28.45  Low: 15.38
Average Vol(K): 3-Month: 553 (K)  10-Days: 436 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MYGN ] has closed above bottom band by 38.6%. Bollinger Bands are 7.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.74 - 19.84 19.84 - 19.92
Low: 18.54 - 18.64 18.64 - 18.72
Close: 18.7 - 18.86 18.86 - 18.99

Company Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Headline News

Thu, 17 Nov 2022
GeneSight mental health monitor reveals gap o - EurekAlert

Mon, 14 Nov 2022
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment - Nasdaq

Tue, 08 Nov 2022
Myriad Genetics (NASDAQ:MYGN) Releases FY 2022 Earnings Guidance - MarketBeat

Thu, 03 Nov 2022
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls - Zacks Investment Research

Thu, 03 Nov 2022
Myriad Genetics (MYGN) To Share Guarded BRCA Variant Information In Public Database - Forbes

Tue, 01 Nov 2022
Healthcare Stocks on the Move Tuesday: ABMD, SONN, ARAV, ATAI, CTLT, TIL, MYGN, BCRX - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 81 (M)
Shares Float 74 (M)
% Held by Insiders 1.9 (%)
% Held by Institutions 102.3 (%)
Shares Short 3,850 (K)
Shares Short P.Month 3,780 (K)

Stock Financials

EPS -0.11
EPS Est Next Qtl 0.25
EPS Est This Year 1.02
EPS Est Next Year 1.19
Book Value (p.s.) 11.32
Profit Margin (%) -11.7
Operating Margin (%) -8.9
Return on Assets (ttm) -2.9
Return on Equity (ttm) -8.2
Qtrly Rev. Growth -6.5
Gross Profit (p.s.) 6.08
Sales Per Share 8.16
EBITDA (p.s.) -0.09
Qtrly Earnings Growth 0
Operating Cash Flow -109 (M)
Levered Free Cash Flow -84 (M)

Stock Valuations

PE Ratio -171.37
PEG Ratio 7.1
Price to Book value 1.66
Price to Sales 2.3
Price to Cash Flow -14.08

Stock Dividends

Dividend 1.75
Forward Dividend 0
Dividend Yield 9.2%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 2009-01-07
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.